Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]
News [14840]
Articles [105]
Editorials [3]
Conferences [245]
elearning [21]
Response and resistance with BRAF inhibitors: Mechanisms, markers and...
Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA
Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions ( Dr Keith Flaherty - Massachusetts General Hospital Cancer Centre, Boston, USA )
19 Mar 2015
Targeting CDK pathways in cancer treatment
Dr Geoffrey Shapiro - Dana Farber Cancer Institute, Boston, USA
Targeting CDK pathways in cancer treatment ( Dr Geoffrey Shapiro - Dana Farber Cancer Institute, Boston, USA )
11 Mar 2015
DNA repair inhibitors to overcome drug resistance
Dr Ruth Plummer - Newcastle University, Newcastle, UK
DNA repair inhibitors to overcome drug resistance ( Dr Ruth Plummer - Newcastle University, Newcastle, UK )
11 Mar 2015
Refining the role of PARP inhibitors in targeted anticancer therapy
Prof Yves Pommier - National Cancer Institute, Bethesda, USA
Refining the role of PARP inhibitors in targeted anticancer therapy ( Prof Yves Pommier - National Cancer Institute, Bethesda, USA )
11 Mar 2015
Developments in immunotherapy
Prof Lillian Siu - University Health Network, Toronto, Canada
Developments in immunotherapy ( Prof Lillian Siu - University Health Network, Toronto, Canada )
11 Mar 2015
Putting adoptive T cell therapy on the path to regulatory approval
Prof Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
Putting adoptive T cell therapy on the path to regulatory approval ( Prof Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )
10 Mar 2015
Using Hsp90 inhibitors in the clinic: what have we learned?
Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom
Using Hsp90 inhibitors in the clinic: what have we learned? ( Dr Udai Banerji - Institute of Cancer Research, Sutton, United Kingdom )
10 Mar 2015
Radiogenomic evaluation of tumour response to targeted agents
Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA
Radiogenomic evaluation of tumour response to targeted agents ( Dr Ronald Korn - CMO and founder of Imaging Endpoints, Scottsdale, USA )
10 Mar 2015
New drugs and targets in haematological malignancies
Dr Renier Brentjens - Memorial Sloan Kettering Cancer Center, New York, USA
New drugs and targets in haematological malignancies ( Dr Renier Brentjens - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Mar 2015
Mutant-specific kinase inhibitors and TAT highlights
Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France
Mutant-specific kinase inhibitors and TAT highlights ( Prof Jean-Charles Soria - Institut Gustave Roussy, Paris, France )
10 Mar 2015
Drugging the cancer genome to overcome drug resistance
Prof Paul Workman - Institute of Cancer Research, UK
Drugging the cancer genome to overcome drug resistance ( Prof Paul Workman - Institute of Cancer Research, UK )
10 Mar 2015
ecancermedicalscience editor's choice for February 2015
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
ecancermedicalscience editor's choice for February 2015 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
3 Mar 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation